Ahmedabad, Gujarat, 16th May 2025
– Senores Pharmaceuticals Limited, a global research driven pharmaceutical company engaged in developing and manufacturing specialty, niche and complex products for Regulated and Emerging Markets, announced its audited Financial Results for the 4th Quarter of FY25 ended 31st March 2025.
For FY25, Regulated Market Revenue stood at Rs. 244.8 crs, a growth of 69% on a Y-o-Y basis. EBIDTA for Regulated Market business stood at Rs. 101.9 crs, with EBITDA Margin of 38.4%.
Emerging Markets Revenue stood at Rs. 121.2 crs, a growth of 174% on a Y-o-Y basis. Emerging Markets EBITDA Margin stood at 7.0% for FY25.
In the regulated markets currently, company has;
- 22 Own commercial products
- 61 Approved ANDA products
- 51 Pipeline products with 28 CGT opportunity products
- 22 CDMO/CMO commercial products
- 69 CDMO/CMO pipeline products
For the emerging markets currently, company has;
- 285 Approved products
- 636 products under registration
- Presence across more than 40 countries
Commenting on the results, Swapnil Shah, Managing Director, Senores Pharmaceuticals Limited said, “We are pleased to report strong performance for FY25, driven by our strategy of developing niche products for Regulated Markets and expanding our CDMO/CMO operations. At the same time, we have continued to grow our presence and product portfolio in Emerging Markets. Our Total Income and Profit before Tax for FY25 have increased by 91% & 183% respectively on year-on-year basis, and we are optimistic about sustaining this momentum going forward.